Skyepharma raises €112m for buy-back

By Nina Flitman
01 May 2014

Pharmaceutical firm Skyepharma launched a buy-back of its 6.5% 2024 bonds this week after completing a £112m capital raise.

The firm sold 58.68m new ordinary shares through the equity increase, representing 127% of the company’s existing share capital. The firm placing and placing and open offer was priced at 191p per new share, with 11 new shares available for every nine already held.

After the completion of the ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial

Want to learn more? View subscription options